Liaoning Chengda Biotechnology Co., Ltd. (SHA:688739)

SHA:688739 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	3,593	4,365	4,496	4,548	5,797	2,829
Short-Term Investments	-	-	30.12	60.19	291.13	270.72
Trading Asset Securities	1,531	850.47	973.02	1,094	-	3,316
Cash & Short-Term Investments	5,125	5,215	5,500	5,702	6,088	6,416
Cash Growth	-0.03%	-5.17%	-3.55%	-6.33%	-5.12%	194.49%
Accounts Receivable	1,158	1,049	1,077	1,082	1,111	958.17
Other Receivables	1.95	1.87	1.41	11.91	1.63	1.09
Receivables	1,160	1,051	1,078	1,094	1,113	959.27
Inventory	459.14	474.39	459.94	422.42	479.88	385.16
Prepaid Expenses	-	-	-	-	-	2.02
Other Current Assets	37.62	46.31	45.47	30.1	25.15	34.75
Total Current Assets	6,782	6,787	7,083	7,249	7,706	7,798
Property, Plant & Equipment	1,820	1,877	1,961	1,885	1,437	1,228
Long-Term Investments	193.77	171.14	132.37	225.07	258.56	305.31
Other Intangible Assets	815.37	182.02	181.45	178.87	187.21	123.35
Long-Term Deferred Tax Assets	44.14	34.16	35.72	42.39	30.29	25.08
Long-Term Deferred Charges	7.63	632.09	588.54	381.37	187.45	82.06
Other Long-Term Assets	33.25	63.2	69.22	120.21	249.49	231.61
Total Assets	9,696	9,746	10,052	10,081	10,056	9,793

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	158.97	12.19	5.22	15.76	16.33	3.1
Accrued Expenses	86.88	178.91	189.18	158.48	165.97	176.43
Current Portion of Long-Term Debt	4.71	-	-	-	-	-
Current Portion of Leases	-	4.6	5.14	4.86	4.53	4.49
Current Income Taxes Payable	20.87	-	-	26.99	18.86	24.17
Current Unearned Revenue	0.98	1.64	3.65	1.97	0.16	3.1
Other Current Liabilities	3.63	103.3	190.12	148.73	67.12	77.72
Total Current Liabilities	276.04	300.63	393.31	356.79	272.99	289.01
Long-Term Leases	2.41	4.77	10	15.14	17.4	21.91
Long-Term Unearned Revenue	70.11	75.27	85.6	100.79	111.1	120.74
Long-Term Deferred Tax Liabilities	0.13	0.16	0.19	9.5	4.66	9.03
Other Long-Term Liabilities	7.74	11.21	0.01	0.01	0.01	0.02
Total Liabilities	356.44	392.05	489.12	482.23	406.16	440.72

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	416.45	416.45	416.45	416.45	416.45	416.45
Additional Paid-In Capital	5,034	5,034	5,034	5,034	5,034	5,034
Retained Earnings	4,056	4,064	4,262	4,248	4,199	3,901
Treasury Stock	-169.98	-160.78	-149.99	-99.99	-	-
Shareholders' Equity	9,339	9,354	9,562	9,599	9,650	9,352
Total Liabilities & Equity	9,696	9,746	10,052	10,081	10,056	9,793

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	7.12	9.37	15.14	20.01	21.93	26.41
Net Cash (Debt)	5,118	5,206	5,484	5,682	6,066	6,390
Net Cash Growth	0.07%	-5.08%	-3.48%	-6.33%	-5.07%	193.28%
Net Cash Per Share	12.30	12.64	13.28	13.66	14.53	16.75
Filing Date Shares Outstanding	450.47	411.25	411.64	412.86	416.45	416.45
Total Common Shares Outstanding	450.47	411.25	411.64	413.47	416.45	416.45
Working Capital	6,506	6,486	6,690	6,892	7,433	7,509
Book Value Per Share	20.73	22.75	23.23	23.22	23.17	22.46
Tangible Book Value	8,522	9,172	9,381	9,420	9,462	9,229
Tangible Book Value Per Share	18.92	22.30	22.79	22.78	22.72	22.16
Buildings	-	1,096	992.14	912.41	713.81	663.04
Machinery	-	1,492	1,435	1,274	880.16	867.47
Construction In Progress	-	427.4	465.58	438.82	454.03	210.84

Data Source: S&P Global Market Intelligence Last updated: Aug 24, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 11, 2026

Data Sources Report a data error